Researchers from the National Cancer Institute and their collaborators have presented data regarding a MLK3-degrading PROTAC, CEP1347-VHL-02, for treating triple-negative breast cancer.
An RNA interference (RNAi) molecule that selectively targets the KRAS G12V mutation could represent a key advance in the treatment of cancer associated with this oncogenic variant. Researchers at the University of North Carolina (UNC) at Chapel Hill, in collaboration with Enfuego Therapeutics Inc., have developed a new RNAi designed to enter cells through the epidermal growth factor receptor (EGFR), which is commonly overexpressed in tumor cells. This targeted entry pathway could minimize the side effects associated with therapies that affect KRAS.
At the Annual Congress of the European Association for Cancer Research (EACR) in Lisbon, multiple sessions aimed to provide fresh perspectives on the always challenging treatment of cancer, with a strong focus on innovative strategies.
Wuhan Humanwell Pharmaceutical Co. Ltd. has described heterocyclic compounds acting as transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.
Evopoint Biosciences Co. Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to an Aurora kinase A (AURKA; ARK1)-targeting moiety through a linker potentially useful for the treatment of cancer.
Researchers at Queen’s University of Belfast and collaborators have developed a DNA vaccine against high-grade serous ovarian cancer. The vaccine encodes PRAME, which the researchers found to be upregulated in several cohorts of patients with the malignancy.
Sillajen Inc. has recently presented data regarding their threonine tyrosine kinase (TTK) and Polo-like kinase 1 (PLK1) dual inhibitor BAL-0891 as a therapeutic approach for acute myeloid leukemia (AML) treatment. The compound was tested both in vitro and in vivo in the preclinical setting.
Synfini Inc. and O2nix Bio have established a strategic collaboration to co-discover and develop novel drug candidates targeting FTSJ1, a tRNA-modifying enzyme implicated in metastatic cancer cell survival.
About 30%-40% of triple-negative breast cancers (TNBC) show HER2-low status and may benefit from the HER2-directed antibody-drug conjugate trastuzumab deruxtecan (T-DXd). Ataxia-telangiectasia mutated (ATM) kinase plays a crucial role in double-strand break (DSB) repair response, thus inhibitors of ATM, such as AZD-1390, may enhance the effect of DSB inducers, resulting in DNA damage accumulation.
Immuneering Corp.’s phase IIa data from an ongoing trial in pancreatic cancer disclosed June 17 impressed Wall Street and brought renewed attention to the perennially difficult indication, at which drug developers continue to fling themselves with varied mechanisms.
RSS
.jpg?height=488&t=1750428815&width=650 "Interfering RNA (RNAi)")
